Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

NCT00845065 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Boceprevir
OTHER: Placebo
BIOLOGICAL: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC